These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 28847800

  • 21. Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience.
    Buonuomo PS, Macchiaiolo M, Leone G, Valente P, Mastrogiorgio G, Gnazzo M, Rana I, Gonfiantini MV, Gagliardi MG, Romano F, Bartuli A.
    Eur J Prev Cardiol; 2018 Jul; 25(10):1098-1105. PubMed ID: 29785886
    [Abstract] [Full Text] [Related]

  • 22. Low-density lipoprotein apheresis in homozygous familial hypercholesterolemia.
    Mora C, Teruel JL, Navarro JF.
    Am J Cardiol; 2001 Jul 15; 88(2):202-3. PubMed ID: 11463060
    [No Abstract] [Full Text] [Related]

  • 23. Three different schedules of low-density lipoprotein apheresis compared with plasmapheresis in patients with homozygous familial hypercholesterolemia.
    Berger GM, Firth JC, Jacobs P, Wood L, Marais AD, Horak A.
    Am J Med; 1990 Feb 15; 88(2):94-100. PubMed ID: 2105647
    [Abstract] [Full Text] [Related]

  • 24. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E, Vogt A, Crispin A, Altenhofer J, Riks I, Parhofer KG.
    Atherosclerosis; 2017 Apr 15; 259():20-25. PubMed ID: 28279833
    [Abstract] [Full Text] [Related]

  • 25. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I, Berthold HK.
    Atheroscler Suppl; 2015 May 15; 18():28-34. PubMed ID: 25936301
    [Abstract] [Full Text] [Related]

  • 26. Changes in lipoprotein(a), LDL-cholesterol and apolipoprotein B in homozygous familial hypercholesterolaemic patients treated with dextran sulfate LDL-apheresis.
    Lasunción MA, Teruel JL, Alvarez JJ, Carrero P, Ortuño J, Gómez-Coronado D.
    Eur J Clin Invest; 1993 Dec 15; 23(12):819-26. PubMed ID: 8143758
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [A case with homozygote familial hypercholesterolemia treated with LDL apheresis and coronary bypass in adolescence period].
    Altinel E, Cetinkaya S, Kara C, Orün UA, Aydin H, Kutsal A.
    Anadolu Kardiyol Derg; 2008 Jun 15; 8(3):231-2. PubMed ID: 18524734
    [No Abstract] [Full Text] [Related]

  • 33. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
    Luirink IK, Hutten BA, Greber-Platzer S, Kolovou GD, Dann EJ, de Ferranti SD, Taylan C, Bruckert E, Saheb S, Oh J, Driemeyer J, Farnier M, Pape L, Schmitt CP, Novoa FJ, Maeser M, Masana L, Shahrani A, Wiegman A, Groothoff JW.
    Atherosclerosis; 2020 Apr 15; 299():24-31. PubMed ID: 32199148
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. LDL apheresis in a homozygous familial hypercholesterolemic child aged 4.5.
    Stefanutti C, Notarbartolo A, Colloridi V, Nigri A, Vivenzio A, Bertolini S, Bosco G, Berni A, Di Giacomo S, Mazzarella B.
    Artif Organs; 1997 Oct 15; 21(10):1126-7. PubMed ID: 9335372
    [Abstract] [Full Text] [Related]

  • 37. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
    Kayikcioglu M, Tokgozoglu L, Dogan V, Ceyhan C, Tuncez A, Kutlu M, Onrat E, Alici G, Akbulut M, Celik A, Yesilbursa D, Sahin T, Sonmez A, Ozdogan O, Temizhan A, Kilic S, Bayram F, Sabuncu T, Coskun FY, Ildizli M, Durakoglugil E, Kirilmaz B, Yilmaz MB, Yigit Z, Yildirim AB, Gedikli O, Topcu S, Oğuz A, Demir M, Yenerçağ M, Yıldırır A, Demircan S, Yilmaz M, Kaynar LG, Aktan M, Durmus RB, Gokce C, Ozcebe Oİ, Akyol TK, Okutan H, Sag S, Gul OO, Salcioglu Z, Altunkeser BB, Kuku I, Yasar HY, Kurtoglu E, Kose MD, Demircioglu S, Pekkolay Z, Ilhan O, Can LH.
    Atherosclerosis; 2018 Oct 15; 277():341-346. PubMed ID: 30270069
    [Abstract] [Full Text] [Related]

  • 38. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov 15; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 39. Role of LDL apheresis in a case of homozygous familial hypercholesterolemia.
    Naveen T, Biswas A, Wig N, Soneja M, Jorwal P, Durga CS, Singla P, Chaudhary C, Baitha U.
    Drug Discov Ther; 2019 Nov 15; 13(1):59-61. PubMed ID: 30880324
    [Abstract] [Full Text] [Related]

  • 40. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A, Harada-Shiba M, Endo M, Kusakabe N, Tanioka T, Kato H, Shoji T.
    Atherosclerosis; 2006 May 15; 186(1):126-31. PubMed ID: 16043185
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.